Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Sarfo, Fred S ^a,b   Phillips, Richard O ^a,b   Zhang, Jihui ^c   Abass, Mohammed K ^d   Abotsi, Justice ^d   Amoako, Yaw A ^a   Adu Sarkodie, Yaw ^a,b   Robinson, Clive ^c   Wansbrough Jones, Mark H ^c  

^a KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^b KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d MINISTRY OF HEALTH   (Ghana)

Author keywords

Antibiotic therapy; Biomarker; Mycobacterium ulcerans; Mycolactone; Prognosis; Treatment response

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; LIPID; MYCOLACTONE; POLYKETIDE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIABILITY; BURULI ULCER; CHILD; CONTROLLED STUDY; CYTOTOXICITY ASSAY; EMBRYO; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; POLYMERASE CHAIN REACTION; PROGNOSIS; SKIN BIOPSY; SKIN DEFECT; SUBCUTANEOUS TISSUE; TISSUE LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; ULCER HEALING;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; BURULI ULCER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MACROLIDES; MALE; MASS SPECTROMETRY; MICE; MIDDLE AGED; MYCOBACTERIUM ULCERANS; SKIN; SUBCUTANEOUS TISSUE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84899494157     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-202     Document Type: Article

References (25)

1. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 2008, 25:447-454. 10.1039/b803101k, 2730631,2730631, 18497894.
2. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, Small PL. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 2005, 7:1295-1304. 10.1111/j.1462-5822.2005.00557.x, 16098217.
3. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, Tanguy M, Cole ST, Small PL, Demangel C. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 2005, 7:1187-1196. 10.1111/j.1462-5822.2005.00546.x, 16008585.
4. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, Albert ML, Demangel C. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 2007, 204:1395-1403. 10.1084/jem.20070234, 2118602, 17517970.
5. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, Foxwell BM. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 1999, 163:3928-3935.
6. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J. Mycolactone-mediated inhibition of tumour necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 2007, 75:3979-3988. 10.1128/IAI.00290-07, 1951989, 17517872.
7. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, Jenkin GA, Johnson PD, Davies JK, Lee RE, Adusumilli S, Garnier T, Haydock SF, Leadlay PF, Cole ST. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 2004, 101:1345-1349. 10.1073/pnas.0305877101, 337055, 14736915.
8. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, Small PL. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999, 283:854-857. 10.1126/science.283.5403.854, 9933171.
9. Dobos KM, Small PL, Deslauriers M, Quinn FD, King CH. Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect Immun 2001, 69(11):7182-7186. 10.1128/IAI.69.11.7182-7186.2001, 100123, 11598099.
10. Bozzo C, Tiberio R, Graziola F, Pertusi G, Valente G, Colombo E, Small PL, Leigheb G. A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and HaCaT cells. Microbes Infect 2010, 12(14-15):1258-1263.
11. Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, Tarelli E, Asiedu KB, Small PL, Wansbrough-Jones MH. Detection of Mycolactone A/B in Mycobacterium ulcerans-infected human tissues. PLoS Negl Trop Dis 2010, 4:e325.
12. Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 2009, 182(4):2194-2202. 10.4049/jimmunol.0802294, 19201873.
13. Guenin-Macé L, Carrette F, Asperti-Boursin F, Le Bon A, Caleechurn L, Di Bartolo V, Fontanet A, Bismuth G, Demangel C. Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci U S A 2011, 108(31):12833-12838. 10.1073/pnas.1016496108, 3150933, 21768364.
14. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, Lartey A, Tetteh I, Wansbrough-Jones M. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010, 54:3678-3685. 10.1128/AAC.00299-10, 2935024, 20566765.
15. Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, Wansbrough-Jones M, Grosset JH. Microbiological, histological, immunological and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis 2013, 7(3):e2101. 10.1371/journal.pntd.0002101, 3597478, 23516649.
16. Phillips RO, Sarfo FS, Osei-Sarpong F, Boateng A, Tetteh I, Lartey A, Adentwe E, Opare W, Asiedu KB, Wansbrough-Jones M. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J Clin Microbiol 2009, 47:924-926. 10.1128/JCM.01842-08, 2668351, 19204098.
17. Marsollier L, Brodin P, Jackson M, Kordulakova J, Tafelmeyer P, Carbonnelle E, Aubry J, Milon G, Legras P, Andre JP, Leroy C, Cottin J, Guilou ML, Reysset G, Cole ST. Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog 2007, 3(5):e62. 10.1371/journal.ppat.0030062, 1864991, 17480118.
18. Phillips RO, Sarfo FS, Abass MK, Abotsi J, Tuah W, Forson M, Amoako YA, Thompson W, Asiedu K, Wansbrough-Jones M. Clinical and bacteriological efficacy of combination of rifampicin and streptomycin for 2 weeks followed by rifampicin and clarithromycin for 6 weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother In press article, In press article.
19. Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng NY, Sarfo FS, Jansson M, Huber KL, Herbinger KH, Battke F, Loscher T, Ohene A, Bretzel G. Detection of viable Mycobacterium ulcerans in clinical samples by a novel combined 16S rRNA reverse transcriptase/IS2404 real-time qPCR assay. PLoS Negl Trop Dis 2012, 6(8):e1756. 10.1371/journal.pntd.0001756, 3429398, 22953006.
20. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005, 49:3182-3186. 10.1128/AAC.49.8.3182-3186.2005, 1196249, 16048922.
21. Phillips RO, Sarfo FS, Nana B, Abass KM, Opare W, Amoako Y, Adentwe E, Fleischer B, Adjei O, Asiedu K, Wansbrough-Jones M. Clinical and bacteriological response of Buruli ulcer patients in Ghana to treatment with rifampicin streptomycin for 7 days per week for 8 weeks compared with rifampicin-streptomycin for 2 weeks followed by rifampicin and clarithromycin for 6 weeks. WHO Annual meeting on Buruli ulcer 2010, 70-71. http://www.who.int/buruli/information/Buruli_meeting_Abstracts_2011_ENG.pdf.
22. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010, 375(9715):664-672. 10.1016/S0140-6736(09)61962-0, 20137805.
23. Gronberg A, Zettergren L, Bergh K, Stahle M, Heilborn J, Angeby K, Small PL, Akuffo H, Britton S. Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity. PLoS One 2010, 5(11):e13839. 10.1371/journal.pone.0013839, 2973957, 21079804.
24. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008, 16(5):585-601. 10.1111/j.1524-475X.2008.00410.x, 19128254.
25. Guenin-Macé L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, Danckaert A, Ruf MT, Mostowy S, Zurzolo C, Bousso P, Chretien F, Carlier MF, Demangel C. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest 2013, 123(4):1501-1512. 10.1172/JCI66576, 3613928, 23549080.